Consequently, the presence of mutations in STAG2, SRSF2 and/or RUNX1 distinguishes between two different prognostic subgroups displaying specific clinical characteristics and outcomes similar to high-risk (with at least one mutation in these genes) and low-risk (without any of these genes altered) MDS patients without +8. The gene discussed is RUNX1; the disease is myelodysplastic syndrome.